483 related articles for article (PubMed ID: 23074282)
21. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
22. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
Fries C; Burack WR
Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye.
Li AH; Forestier E; Rosenquist R; Roos G
Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
25. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
26. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
[TBL] [Abstract][Full Text] [Related]
27. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
Jia YP; Liu GL; Zhang LP
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
[TBL] [Abstract][Full Text] [Related]
28. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
Liu JY; Li ZG; Gao C; Cui L; Wu MY
Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
[TBL] [Abstract][Full Text] [Related]
29. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
[TBL] [Abstract][Full Text] [Related]
30. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
31. Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.
Li A; Zhou J; Zuckerman D; Rue M; Dalton V; Lyons C; Silverman LB; Sallan SE; Gribben JG
Blood; 2003 Dec; 102(13):4520-6. PubMed ID: 12946997
[TBL] [Abstract][Full Text] [Related]
32. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
33. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
[TBL] [Abstract][Full Text] [Related]
34. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
Theunissen PMJ; de Bie M; van Zessen D; de Haas V; Stubbs AP; van der Velden VHJ
Leuk Res; 2019 Jan; 76():98-104. PubMed ID: 30389174
[TBL] [Abstract][Full Text] [Related]
35. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
[TBL] [Abstract][Full Text] [Related]
36. Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy.
Wu NH; Lu SG; Zhu P; Peng YY
Pediatr Hematol Oncol; 1996; 13(3):257-63. PubMed ID: 8735342
[TBL] [Abstract][Full Text] [Related]
37. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?
Campana D
Curr Hematol Malig Rep; 2012 Jun; 7(2):170-7. PubMed ID: 22373809
[TBL] [Abstract][Full Text] [Related]
38. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones.
Salson M; Giraud M; Caillault A; Grardel N; Duployez N; Ferret Y; Duez M; Herbert R; Rocher T; Sebda S; Quief S; Villenet C; Figeac M; Preudhomme C
Leuk Res; 2017 Feb; 53():1-7. PubMed ID: 27930944
[TBL] [Abstract][Full Text] [Related]
39. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
40. Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA - 2009 protocol.
Rocha JMC; Xavier SG; Souza MEL; Murao M; de Oliveira BM
Pediatr Hematol Oncol; 2019 Aug; 36(5):287-301. PubMed ID: 31287348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]